Literature DB >> 28779847

Efficacy of intralesional sodium thiosulfate injections for disabling tumoral calcinosis: Two cases.

J Goossens1, M Courbebaisse2, E Caudron3, C Bahans4, V Vacquerie5, J Melchior6, P Vergne Salle7, C Moesch8, M Daudon9, V Frocht9, P Richette1, Hang-Korng Ea10, V Guigonis11.   

Abstract

INTRODUCTION: Tumoral calcinosis (TC) is a difficult-to-treat complication that can occur during several diseases such as dermatomyositis or genetic hyperphosphatemia. It is a painful and disabling condition that can lead to local complications including joint mobility reduction, cutaneous ulceration and superinfection. For the largest lesions, the treatment relies essentially on surgery. Intravenous sodium thiosulfate (STS) is efficient to treat calciphylaxis in patients undergoing hemodialysis. Local injections of STS seem efficient in superficial calcifications.
OBJECTIVE: To report the efficacy and safety of intra-lesional injections of STS in tumoral calcinosis.
RESULTS: We report two cases of successful intra-lesional injections of STS. A 44-year-old woman, with a history of dermatomyositis, presenting large subcutaneous calcifications in the right elbow, and a 42-year-old man, with a history of familial tumoral calcinosis, presenting large intramuscular calcifications in the right buttock, received weekly intra-lesional of 1-3g STS injections for 12 and 21 months, respectively. In both cases, the treatment relieved pain and greatly reduced the tumoral calcinosis with a very significant functional improvement without specific adverse effects. In case 1, TC size decreased from 28.7*56.0mm at baseline to 21.5*30.6mm at M12 treatment (59% reduction). In case 2, TC reduced from 167.5*204.3mm at baseline to 86.2*85.2mm at M21 treatment (79% reduction).
CONCLUSION: Local injection of STS could be a promising therapeutic strategy for large and deep TC lesions and could therefore be an alternative to surgery.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dermatomyositis; FGF23; Familial tumoral calcinosis; Sodium thiosulfate

Mesh:

Substances:

Year:  2017        PMID: 28779847     DOI: 10.1016/j.semarthrit.2017.05.013

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  6 in total

Review 1.  Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature.

Authors:  M Chakhtoura; M S Ramnitz; N Khoury; G Nemer; N Shabb; A Abchee; A Berberi; M Hourani; M Collins; S Ichikawa; G El Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2018-06-20       Impact factor: 4.507

Review 2.  Subcutaneous calcinosis: Is it different between systemic sclerosis and dermatomyositis?

Authors:  Antonia Valenzuela; Lorinda Chung
Journal:  J Scleroderma Relat Disord       Date:  2021-10-28

Review 3.  Hyperphosphatemic Tumoral Calcinosis: Pathogenesis, Clinical Presentation, and Challenges in Management.

Authors:  Alison M Boyce; Alisa E Lee; Kelly L Roszko; Rachel I Gafni
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-08       Impact factor: 5.555

Review 4.  Juxta-articular tumoral calcinosis associated with the temporomandibular joint: a case report and concise review.

Authors:  Yang Sha; Kanglun Hong; Melvin Kang Ming Liew; Jing Li Lum; Raymond Chung Wen Wong
Journal:  BMC Oral Health       Date:  2019-07-09       Impact factor: 2.757

Review 5.  Local, non-systemic, and minimally invasive therapies for calcinosis cutis: a systematic review.

Authors:  Joanna Nowaczyk; Michał Zawistowski; Piotr Fiedor
Journal:  Arch Dermatol Res       Date:  2021-06-24       Impact factor: 3.033

6.  Therapeutic effect of intravenous sodium thiosulfate for uremic pruritus in hemodialysis patients.

Authors:  Yu-Huan Song; Si-Yang Wang; Jia-Hui Lang; Yue-Fei Xiao; Guang-Yan Cai; Xiang-Mei Chen
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.